Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Radiation. University of California, San Francisco, Comprehensive Cancer Center, San Francisco, CA, United States

Survival: 19.3 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: San Francisco, CA
Hospital: University of California, San Francisco, Comprehensive Cancer Center
Journal: Link
Date: 2/2009

This study involved 65 glioblastoma multiforme or gliosarcoma patients with a median age of 55 years (range of 22-77). The percentages of male and female patients were not given.

Patients were treated with radiotherapy. During and after this therapy, patients were also given the chemotherapy agent temozolomide and the biologic therapy erlotinib. Erlotinib is a small molecular inhibitor of a protein (epidermal growth factor receptor tyrosine kinase) involved in cell growth and survival.

The maximum toxicity level reported was of grade 4, including two cases of neutropenia and one case each of thrombocytopenia and fatigue. Also, four cases each of grade 3 fatigue and rash were reported.

The reported median overall survival was 19.3 months.

This study was partially funded by Genentech, makers of erlotinib (brand name: Tarceva).

Correspondence: Dr. Michael Prados; email:

E-mail to a Friend Email Physician More Information